These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 35087523)

  • 1. Novel Molecular Determinants of Response or Resistance to Immune Checkpoint Inhibitor Therapies in Melanoma.
    Zhang W; Kong Y; Li Y; Shi F; Lyu J; Sheng C; Wang S; Wang Q
    Front Immunol; 2021; 12():798474. PubMed ID: 35087523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sex Disparities of Genomic Determinants in Response to Immune Checkpoint Inhibitors in Melanoma.
    Shi F; Zhang W; Yang Y; Yang Y; Zhao J; Xie M; Sheng C; Wang S; Wang Q
    Front Immunol; 2021; 12():721409. PubMed ID: 34795662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A mutational signature and significantly mutated driver genes associated with immune checkpoint inhibitor response across multiple cancers.
    Wang Q; Zhang W; Guo Y; Shi F; Li Y; Kong Y; Lyu J; Wang S
    Int Immunopharmacol; 2023 Mar; 116():109821. PubMed ID: 36753986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Combined Proteomic and Transcriptomic Signature Is Predictive of Response to Anti-PD-1 Treatment: A Retrospective Study in Metastatic Melanoma Patients.
    Mallardo D; Fordellone M; White A; Vowinckel J; Bailey M; Sparano F; Sorrentino A; Mallardo M; Facchini BA; De Filippi R; Ferrara G; Vanella V; Beeler K; Chiodini P; Cesano A; Warren S; Ascierto PA
    Int J Mol Sci; 2024 Aug; 25(17):. PubMed ID: 39273294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors.
    Zhang L; Han X; Shi Y
    JAMA Netw Open; 2020 Aug; 3(8):e2013201. PubMed ID: 32845327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
    Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer.
    Wang SJ; Khullar K; Kim S; Yegya-Raman N; Malhotra J; Groisberg R; Crayton SH; Silk AW; Nosher JL; Gentile MA; Mehnert JM; Jabbour SK
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association of sex-biased ATRX mutation in female gastric cancer patients with enhanced immunotherapy-related anticancer immunity.
    Ge Y; Wei F; Du G; Fei G; Li W; Li X; Chu J; Wei P
    BMC Cancer; 2021 Mar; 21(1):240. PubMed ID: 33678158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SETBP1 mutation determines sensitivity to immune checkpoint inhibitors in melanoma and NSCLC.
    An F; Zhang W; Guo Y; Shi F; Kong Y; Tang L; Han C; Wang Q
    Aging (Albany NY); 2023 Aug; 15(15):7476-7495. PubMed ID: 37535001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Innate immune checkpoint inhibitor resistance is associated with melanoma sub-types exhibiting invasive and de-differentiated gene expression signatures.
    Hossain SM; Gimenez G; Stockwell PA; Tsai P; Print CG; Rys J; Cybulska-Stopa B; Ratajska M; Harazin-Lechowska A; Almomani S; Jackson C; Chatterjee A; Eccles MR
    Front Immunol; 2022; 13():955063. PubMed ID: 36248850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Deleterious
    Zhang K; Hong X; Song Z; Xu Y; Li C; Wang G; Zhang Y; Zhao X; Zhao Z; Zhao J; Huang M; Huang D; Qi C; Gao C; Cai S; Gu F; Hu Y; Xu C; Wang W; Lou Z; Zhang Y; Liu L
    Clin Cancer Res; 2020 Jul; 26(14):3649-3661. PubMed ID: 32241817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition.
    Knispel S; Gassenmaier M; Menzies AM; Loquai C; Johnson DB; Franklin C; Gutzmer R; Hassel JC; Weishaupt C; Eigentler T; Schilling B; Schummer P; Sirokay J; Kiecker F; Owen CN; Fleischer MI; Cann C; Kähler KC; Mohr P; Bluhm L; Niebel D; Thoms KM; Goldinger SM; Reinhardt L; Meier F; Berking C; Reinhard R; Susok L; Ascierto PA; Drexler K; Pföhler C; Tietze J; Heinzerling L; Livingstone E; Ugurel S; Long GV; Stang A; Schadendorf D; Zimmer L
    Eur J Cancer; 2021 May; 148():61-75. PubMed ID: 33735811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non-small cell lung cancer.
    Zhang W; Shi F; Kong Y; Li Y; Sheng C; Wang S; Wang Q
    Cancer Med; 2022 Feb; 11(3):676-691. PubMed ID: 34862763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive Impact of Tumor Mutational Burden on Real-World Outcomes of First-Line Immune Checkpoint Inhibition in Metastatic Melanoma.
    Andrews MC; Li G; Graf RP; Fisher VA; Mitchell J; Aboosaiedi A; O'Rourke H; Shackleton M; Iddawela M; Oxnard GR; Huang RSP
    JCO Precis Oncol; 2024 Jun; 8():e2300640. PubMed ID: 38848517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Size matters: integrating tumour volume and immune activation signatures predicts immunotherapy response.
    Lim SY; da Silva IP; Adegoke NA; Lo SN; Menzies AM; Carlino MS; Scolyer RA; Long GV; Lee JH; Rizos H
    Mol Cancer; 2024 Oct; 23(1):228. PubMed ID: 39394099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Undifferentiated and Dedifferentiated Metastatic Melanomas Masquerading as Soft Tissue Sarcomas: Mutational Signature Analysis and Immunotherapy Response.
    Kasago IS; Chatila WK; Lezcano CM; Febres-Aldana CA; Schultz N; Vanderbilt C; Dogan S; Bartlett EK; D'Angelo SP; Tap WD; Singer S; Ladanyi M; Shoushtari AN; Busam KJ; Hameed M
    Mod Pathol; 2023 Aug; 36(8):100165. PubMed ID: 36990277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
    Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
    JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers.
    Yang X; Hu Y; Yang K; Wang D; Lin J; Long J; Xie F; Mao J; Bian J; Guan M; Pan J; Huo L; Hu K; Yang X; Mao Y; Sang X; Zhang J; Wang X; Zhang H; Zhao H
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33972389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and Validation of
    Li Z; Wang X; Yang Y; Shi F; Zhang W; Wang Q; Wang S
    Cells; 2022 Nov; 11(23):. PubMed ID: 36497098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic evaluation of the predictive gene expression signatures of immune checkpoint inhibitors in metastatic melanoma.
    Coleman S; Xie M; Tarhini AA; Tan AC
    Mol Carcinog; 2023 Jan; 62(1):77-89. PubMed ID: 35781709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.